Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia
2021 Update on ET in BC: Palbociclib+ET in HR+/HER2- Normal Disease After Neoadjuvant Chemo & Surgery, Abemaciclib in High-Risk Early Stage HR+/HER2- Disease - Are There IDFS Benefits?
Login to view comments.
Click here to Login
2021